Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...

Compass Therapeutics has announced top-line data from its ongoing COMPANION-002 trial investigating its antibody-based ...

First NK Cell Therapy Approval Expected By 2028 Says Kuick Research In Its New Research Study On Global NK Cell Therapy ...

Learn more about whether Haleon plc or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, ...

Learn more about whether Jazz Pharmaceuticals plc or Novo Nordisk A/S is a better investment based on AAII's A+ Investor ...

Researchers laid out nutritional management strategies for clinicians to offer patients before and after bariatric surgery to ...

Tovecimig, formerly known as CTX-009, is a bispecific antibody that blocks the Delta-like ligand 4 and vascular endothelial growth factor A signaling pathways.

An international research team led by the Chinese University of Hong Kong (CUHK) has achieved a breakthrough in the field of ...

Compass Therapeutics, Inc. (NASDAQ:CMPX) announced statistically significant topline data on Tuesday on the primary efficacy ...

Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to ...

Compass Therapeutics (NASDAQ:CMPX) stock gains as its oncology drug tovecimig hits main goal in a Phase 2/3 trial for biliary ...

Shares of oncology-focused biopharma Compass Therapeutics (NASDAQ:CMPX) added ~11% in the premarket on Tuesday after the ...